Tailoring Treatment in Cardiovascular Diseases: The Role of Targeted Therapies

Razan Dankar,Jad Wehbi,Marwan M. Refaat

DOI: https://doi.org/10.3390/pharmaceutics16040461

IF: 6.525

2024-03-27

Pharmaceutics

Abstract:Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality around the globe. To address this public health burden, innovative therapeutic agents are being developed to specifically target molecular and genetic markers. Various therapeutic modalities have been implemented, including vaccines, monoclonal or bispecific antibodies, and gene-based therapies. Such drugs precisely target the underlying disease pathophysiology, aiming at notable molecules such as lipid metabolism regulators, proinflammatory cytokines, and growth factors. This review focuses on the latest advancements in different targeted therapies. It provides an insightful overview of the current landscape of targeted cardiovascular therapies, highlighting promising strategies with potential to transform the treatment of CVDs into an era of precision medicine.

pharmacology & pharmacy

What problem does this paper attempt to address?

This paper attempts to address a critical issue in the treatment of cardiovascular diseases (CVDs), namely how to improve therapeutic efficacy, reduce side effects, and achieve personalized medicine through targeted therapies. Specifically, the paper explores the following aspects:

1. **Current Status and Challenges of Cardiovascular Diseases**: Cardiovascular diseases are the leading cause of disability and death worldwide, with their prevalence and mortality rates continuing to rise. Despite significant advances in diagnosis and treatment, CVDs still impose a substantial socioeconomic burden. Additionally, traditional treatment methods show considerable variability in efficacy and side effects among different patients, and the lack of regenerative capacity in cardiac cells can lead to chronic cardiac dysfunction and heart failure following cardiac events.

2. **Development of Targeted Therapies**: To address these challenges, researchers have developed various innovative therapeutic drugs that can specifically target molecular and genetic markers, including vaccines, monoclonal or bispecific antibodies, and gene therapies. These drugs can precisely act on key molecules involved in the pathophysiology of diseases, such as lipid metabolism regulators, pro-inflammatory cytokines, and growth factors.

3. **Overview of Specific Targeted Therapies**:
- **Monoclonal Antibodies (mAbs)**: The paper details several monoclonal antibodies used in the treatment of cardiovascular diseases, such as antibodies targeting PCSK9, ANGPTL3, GP IIb/IIIa, IL-1, and IL-6. These antibodies have shown significant effects in lowering low-density lipoprotein cholesterol (LDL-C), anti-platelet aggregation, and inhibiting inflammation.
- **Bispecific Antibodies (BsAbs)**: The paper discusses the application of bispecific antibodies in the treatment of cardiovascular diseases, particularly their role in promoting stem cell migration to damaged myocardial tissue and enhancing vascular regeneration.
- **Regulatory T Cell-Based Therapies**: The paper also introduces the role of regulatory T cells (Tregs) in inhibiting atherosclerosis and slowing the progression of heart failure.

4. **Future Prospects**: The paper emphasizes the potential of targeted therapies in the treatment of cardiovascular diseases, especially in achieving precision medicine. By integrating patients' genetic information, lifestyle, biomarkers, and disease phenotypes, targeted therapies are expected to provide more individualized and effective treatment options for CVD patients.

In summary, this paper aims to provide new insights and strategies for the treatment of cardiovascular diseases by reviewing the latest advancements in targeted therapies.